NCT05085665View on ClinicalTrials.gov

Loiasis Cross-reactive Antigenemia and Treatment-related Adverse Events

PHASE4CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

July 30, 2021

Primary Completion Date

August 31, 2021

Study Completion Date

September 30, 2021

Conditions
Loiasis
Interventions
DRUG

Ivermectin

single dose, 150 ug/kg

Trial Locations (1)

Unknown

Centre de Recherche sur les Filarioses et autres Maladies Tropicales (CRFilMT), Yaoundé

All Listed Sponsors
collaborator

Center for Research on Filariasis and Other Tropical Diseases, Cameroon

OTHER

lead

Washington University School of Medicine

OTHER

NCT05085665 - Loiasis Cross-reactive Antigenemia and Treatment-related Adverse Events | Biotech Hunter | Biotech Hunter